Drugs / QL2109
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07400744 | Mar → Sep 2026 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06371534 | Apr 2024 → Apr 2025 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07018050 | Sep 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06742138 | Jan 2025 → Dec 2027 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06371534 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-CD38 fully human monoclonal antibody.” NCT07400744 ↗ |
| Route | Subcutaneous | “given 1800 mg subcutaneously” NCT06742138 ↗ |
| Target | CD38 | “Recombinant anti-CD38 fully human monoclonal antibody.” NCT07400744 ↗ |